COVID-19:immunopathogenesis and Immunotherapeutics  

作　　者：Li Yang Shasha Liu Jinyan Liu Zhixin Zhang Xiaochun Wan Bo Huang Youhai Chen Yi Zhang 

机构地区：[1]Biotherapy Center,The First Affiliated Hospital of Zhengzhou University,450052 Zhengzhou,China [2]Institute of Health Management,Health Management Center,Sichuan Provincial People’s Hospital,University of Electronic Science and Technology of China,611731 Chengdu,China [3]Shenzhen Laboratory of Human Antibody Engineering,Institute of Biomedicine and Biotechnology,Shenzhen Institutes of Advanced Technology,Chinese Academy of Sciences,518055 Shenzhen,China [4]Department of Immunology&National Key Laboratory of Medical Molecular Biology,Institute of Basic Medical Sciences,Chinese Academy of Medical Sciences(CAMS)&Peking Union Medical College,100005 Beijing,China [5]Department of Pathology and Laboratory Medicine,School of Medicine,University of Pennsylvania,Philadelphia,PA 19104,USA

出　　处：《Signal Transduction and Targeted Therapy》2020年第1期1327-1334,共8页信号转导与靶向治疗（英文）

基　　金：supported by grants from the Emergency Prevention and Control of COVID-19 Project of Henan Province(grant no.201100310900);the 2020 Science and Technology Project of Henan Province(grant no.202102310039);the National Natural Science Foundation of China(grant nos.91942314,U1804281,81602024);the State’s Key Project of Research and Development Plan(grant nos.2018YFC1313400,2016YFC1303500)。

摘　　要：The recent novel coronavirus disease(COVID-19)outbreak,caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),is seeing a rapid increase in infected patients worldwide.The host immune response to SARS-CoV-2 appears to play a critical role in disease pathogenesis and clinical manifestations.SARS-CoV-2 not only activates antiviral immune responses,but can also cause uncontrolled inflammatory responses characterized by marked pro-inflammatory cytokine release in patients with severe COVID-19,leading to lymphopenia,lymphocyte dysfunction,and granulocyte and monocyte abnormalities.These SARS-CoV-2-induced immune abnormalities may lead to infections by microorganisms,septic shock,and severe multiple organ dysfunction.Therefore,mechanisms underlying immune abnormalities in patients with COVID-19 must be elucidated to guide clinical management of the disease.Moreover,rational management of the immune responses to SARSCoV-2,which includes enhancing anti-viral immunity while inhibiting systemic inflammation,may be key to successful treatment.In this review,we discuss the immunopathology of COVID-19,its potential mechanisms,and clinical implications to aid the development of new therapeutic strategies against COVID-19.

关 键 词：PATHOGENESIS IMMUNITY CLINICAL 

分 类 号：R563.1[医药卫生—呼吸系统]